Physician profile
Ashyln Drake
NPI 1154994903
$5,535.99
in general payments reported to CMS, 2019-2025
28 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $1,888 · 2023: $776 · 2024: $634 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,458 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,458.14 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,293.15 | 2021-2025 | Synchromedii, Kyphon Express II Kyphopak Tray, Inceptiv |
| Abbvie INC. | $1,223.71 | 2022-2025 | |
| Nalu Medical, INC. | $1,093.24 | 2021-2023 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $557.05 | 2021-2025 | Xtampza, Belbuca |
| Lundbeck LLC | $331.71 | 2022-2025 | Vyepti |
| Boston Scientific Corporation | $190.08 | 2022-2025 | Intracept, Superion Indirect Decompression System |
| Vertos Medical, INC. | $99.91 | 2022-2024 | Mild Device Kit |
| Stryker Corporation | $98.46 | 2025 | Omnicurve, Mild Device Kit |
| Ibsa Pharma INC. | $73.06 | 2022-2024 | Tirosint, Licart, Tirosint |
| Pfizer INC. | $65.52 | 2023-2024 | |
| Nevro Corp. | $55.22 | 2022-2024 | Senza |
| Allergan, INC. | $51.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.05 | 2024-2025 | Relistor |
| Biotronik Nro, INC. | $43.58 | 2025 | Prospera |
| Fidia Pharma USA INC. | $43.56 | 2022-2025 | Hymovis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.58 | 2022 | |
| Bioventus LLC | $23.59 | 2021 | |
| Lilly USA, LLC | $23.01 | 2022 | |
| Horizon Therapeutics Plc | $22.66 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.50 | 2025 | Zilretta |
| Grt US Holding, INC. | $20.87 | 2021 | |
| Averitas Pharma INC. | $20.85 | 2023 | Qutenza |
| Almatica Pharma LLC | $20.58 | 2022 | |
| Si-Bone, INC. | $17.47 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.01 | 2022 | |
| Hikma Pharmaceuticals USA | $16.91 | 2022 | |
| Electronic Waveform Lab, INC. | $16.83 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.24 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashyln Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.